Resources

Learn more about EvaThera, MTTI, and the future of radiopharmaceuticals. 

Resources

Learn more about EvaThera, MTTI, and the future of radiopharmaceuticals. 

EvaThera Brochure

Innovative, therapeutic, and diagnostic targeted radiopharmaceuticals filling critical gaps in oncologic care.

Read more

The EvaThera Story

EvaThera Theranostics are a new generation of Evans Blue-based molecules with strong affinity for albumin.

Read more

EBTATE Handout

177Lu-DOTA-EBTATE

Read more

EBRGD Handout

177Lu-DOTA-EBRGD

Read more

Xiaoyuan Chen, PhD EBTATE Explanatory Video

New treatment proves more effective and less toxic for neuroendocrine tumor patients

Read more

EBRGD acts synergistically with checkpoint inhibitors

Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy

Read more

EBTATE for Imaging and Treatment of Thyroid Cancer

177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer

Read more

EBTATE Reduces Tumor Size in Patients with NETs

Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study.

Read more

EBTATE safety and efficacy in patients with NETs

Peptide Receptor Radionuclide Therapy of Late-stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE

Read more

SNMMI 2022 Accepted Oral Abstract: EBTATE safety with and without Amino Acid Infusion

Evaluation of Safety, Biodistribution and Dosimetry of a long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE with and without Amino Acid Infusion

Read more

Ready to learn more?

Reach out to us to learn more about EvaThera, MTTI, and the future of radiopharmaceuticals

© 2021 Molecular Targeting Technologies, INC. All Rights Reserved.

PHONE
610-738-7938

EMAIL
INFO@EVATHERA.COM